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Edited by Gianni CesareniAbstract Alternative splicing leads to multiple proteins from
individual genes and the most common deviation from the norm
is precise exon omission. Mutations that cause this can be found
deep in introns, especially downstream of the cassette exon. This
review summarises what is known about these intronic splicing
enhancers and their RNA-binding proteins that cause spliceo-
some assembly on the upstream exon.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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On average less than 10% of a gene makes it into the ﬁnal
messenger RNA. The small expressed regions (exons) that are
selected depend on where the transcription machinery starts
and where polyadenylation ends the transcribed pre-messenger
RNA [1,2]. Alternative transcripts can result from splicing
these alternative terminal exons to common internal exons.
Internal intervening sequences (introns) can have alternate 5 0
or 3 0 splice sites and ﬁnally optional exons can be slotted into
the mRNA like a ‘cassette’. In the last few years the alternative
splicing ﬁeld has become considerably more complicated in
part due to genomic technologies which have started to unravel
the coordinated control of splicing events [3–5] but also because
splicing is increasingly recognized as an integral part of tran-
scription rather than as an isolated process. In addition most
of the canonical splicing factors have been found to also be
involved in other gene expression processes [5,6]. These
discoveries have recently been described as bringing splicing
research ‘to the edge of chaos’ [5]. To navigate a path through
a ﬁeld where there are an increasing number of exceptions to a
diminishing set of rules this review will focus on the current
knowledge of the most common type of alternative splicing,
the cassette exon type, and how it is controlled by the most
abundant form of pre-mRNA namely introns.Abbreviations: ISE, intronic splicing enhancer; RBP, RNA-binding
protein; hnRNP, heterogeneous nuclear ribonucleoprotein; snRNP,
small nuclear ribonucleoprotein
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doi:10.1016/j.febslet.2007.08.012Intronic sequences can either enhance or inhibit splicing and
can be revealed by disease-causing point mutations. For exam-
ples several disease causing mutations occur in the +20 to 40
region downstream of exons to cause them to be skipped
[7–9]. These sequences may be necessary for incorporation of
the exon under all circumstances or they may be regulated in
speciﬁc tissues or developmental stages. For example, the var-
iable exons v8 and v9 of CD44 are usually excluded in adult
tissues but when incorporated they tend to be together and this
may be due to intronic splicing enhancers (ISEs) containing
UGG repeats found at the +85 and +135 positions in their
respective downstream introns [10]. Another enhancer is found
in the +15 to 68 position downstream of a neuron-speciﬁc exon
of Agrin which confers heparin binding at the neuromuscular
junction [11]. The speciﬁc nuclear factors that cause alternative
splicing through these ISEs have not yet been determined.2. Downstream intronic enhancer proteins
In several cases however these trans-acting eﬀectors of ISE
action have been characterized (Fig. 1). TIA-1 is an important
ISE protein that binds pyrimidine-rich sequences between the
+47 and 62 positions downstream of exon 9 of the cystic ﬁbro-
sis transmembrane conductance regulator; mutations that
aﬀect exon 9 inclusion are associated with the disease [12].
The closest enhancers to the downstream 5 0 splice site that
bind trans-acting factors are exempliﬁed by the U-rich enhan-
cer in the +6 to 20 position downstream of Fas exon 6. Skip-
ping of exon 6 turns Fas from a pro-apoptotic transmembrane
receptor into an anti-apoptotic soluble protein and exon skip-
ping can be caused by downregulation of TIA-1 and the closely
related TIAR protein which bind the U-rich enhancer [13]. The
eﬀect of TIA-1 can be further enhanced by regulated phos-
phorylation [14]. A stem–loop in COL2A1 that starts just 4
bases downstream of an alternative exon can enhance its rec-
ognition and there appear to be dynamic interactions between
the stem and TIA-1 which binds the unravelled stem [15]. TIA-
1 also enhances an upstream exon in the mutually exclusive
exon systems of b-tropomyosin and FGFR2 [16] and it is
perhaps the most versatile intronic enhancer as it also exerts
a positive inﬂuence over the terminal calcitonin exon from a
position 200 nucleotides downstream of its polyadenylation
site [2]. Because of its aﬃnity for U-rich sequences TIA-1 is
often antagonised by the archetypal splicing inhibitor, the
pyrimidine tract binding protein PTB [12,13].
Further examples of RNA-binding protein mediated
enhancement at ISEs come from the model system of chickenblished by Elsevier B.V. All rights reserved.
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Fig. 1. RNA-binding proteins bind intronic splicing enhancers downstream of cassette exons. The RNA-binding proteins (dealt with in the text) are
depicted above their ISE, in the relative position downstream of the alternative exon indicated by the scale above. The bound motif is indicated below
each RNA-binding protein (RBP) and the alternatively spliced gene’s names are indicated to the right of each example.
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sequences between the +10 and +130 positions downstream
of exon 17 allow enhancement by the binding of Splicing Fac-
tor 1 [17]. In the same gene (TnT), embryonic muscle-speciﬁc
splicing of another exon (exon 5) is controlled by upregulation
of the CELF family RNA-binding protein ETR-3 which acts
at two UG-rich enhancer sequences around +20 and +70
downstream of the exon [18].3. Neural exon inclusion
The tissue with the most intricate alternative splicing is the
brain where AS events are especially enriched in signalingpathways, cytoskeletal components and vesicular transport
[3]. NAPOR, another CELF family protein, is involved in
brain region-speciﬁc splicing and there is a binding element
for it between 150 and 440 bases downstream of the NMDA
R1 receptor exon 21 (also known as the CI exon) that is impor-
tant for post-synaptic traﬃcking [19]. As introns are coated
with multiple proteins in heterogeneous nuclear ribonucleo-
protein (hnRNP) particles they are generally subject to combi-
natorial control and exon 21 is no exception as it is also
stimulated by hnRNPH which binds a G-rich sequence adja-
cent to the 5 0 splice site and this is antagonized by hnRNPA1
among other factors [20].
The neuron-speciﬁc protein Tau has 3 or 4 microtubule-
binding domains depending on inclusion of exon 10 and the
J.P. Venables / FEBS Letters 581 (2007) 4127–4131 4129normal balance between these isoforms of 1:1 is crucial for
axonal transport and perturbation of splicing causes fronto-
temporal dementia (FTDP-17). An expression screening
strategy was devised to look for factors that cause inclusion
of the exon. Transfection of a cDNA expression library caused
a minigene containing Tau exon 10 and its ﬂanking regions to
express GFP in frame and candidate causative factors were
isolated. One of the proteins was RBM4 which is overexpres-
sed in aﬀected regions of Tauopathy patients, consistent with
a physiological role in Tau splicing [21]. RBM4 binds a UC-
CUUCUUG motif one hundred nucleotides downstream of
exon 10 and over and under-expressing RBM4 and mutating
its binding site conﬁrmed its role.4. Fox proteins
The most studied intronic enhancer proteins are Fox-1 and
Fox-2. Mouse Fox-1 is expressed predominantly in brain but
also in muscle and heart [22]. Fox proteins act at UGCAUG
motifs which are highly enriched in the 400 nucleotides down-
stream of brain-enriched exons [3,23]. For example, UGC-
AUG is found in an enhancer between 17 and 142 bases
downstream of the neuron-speciﬁc N1 exon of mouse cSrc.
Overexpression and downregulation of Fox-1 regulated the
N1 exon in cell culture concordantly. While the Fox-binding
motif is important for splicing [24] the situation is, as ever,
more complicated as several other speciﬁc RNA-binding pro-
teins are also associated with the enhancer [25]. In the EWS
gene another short exon, has a Fox-responsive enhancer 23
nucleotides downstream [26]. Fox-2 which is expressed in
mouse erythroblasts [27] also binds 3 UGCAUG motifs in
the +90 to 132 region downstream of exon 16, the muscle,
brain and erythrocyte-speciﬁc exon of Protein 4.1R. Regulated
inclusion of this exon is crucial for red blood cell membrane
biogenesis, late during erythroid development, as it increases
the transmembrane protein’s aﬃnity for cytoskeletal compo-
nents. Using a minigene in diﬀerentiating cells showed that
mutations in any of the motifs reduced exon inclusion [28].
Although there is an apparent clustering of ISEs in the ﬁrst
few hundred nucleotides after the 5 0 splice site of cassette exons
(Fig. 1) they can also be further downstream. For example, any
of ﬁve Fox-binding motifs in the 3 0-most 500 nucleotides of the
downstream intron could be mutated to the detriment of splic-
ing of the Fibronectin EDB exon [22,26,29–31]. Consistently,
Fox-2 like the EDB exon is predominantly expressed during
embryogenesis [26]. Some ISEs with UGCAUG motifs may
even be more than a kilobase downstream [32,33].XX
Fig. 2. The Yin and Yang of intronic splicing control. Enhancement of
5 0 splice sites increases competition for the downstream 3 0 splice site
(solid lines) while interference with the either 3 0 splice site reduces
competition for the upstream 5 0 splice site (dashed lines). The net result
of splicing factor binding in the upstream exon is to enhance skipping
or inhibit inclusion, whereas binding in the downstream intron
enhances inclusion or inhibits exclusion.5. Complexities of splicing control
With so much adjacent sequence aﬀecting exon deﬁnition
there are naturally many competing inﬂuences and the exam-
ples above form a subset of all possible mechanisms. For
example, sequences even further away, beyond the adjacent
introns and exons, can control splicing [5,34]. Intronic ele-
ments can also act in pairs, so distant locations can be drawn
together either directly, by base pairing, or by binding to mu-
tual proteins, and this can either shorten introns and enhance
splicing or ‘loop out’ and occlude exons to inhibit exon inclu-sion [35–38]. Clearly mutations of splice sites will have a direct
eﬀect and sequences immediately adjacent to splice sites can
also inhibit exons by sequestering them by stable base pairing.
Conversely mutations in structural elements that overlap pseu-
do-exons can lead to cryptic exon inclusion [5,38,39].6. Upstream inhibitors, downstream enhancers
With respect to inﬂuences that disrupt splicing there is a
clear diﬀerence between 5 0 and 3 0 splice sites. While the 5 0
splice site is a degenerate 8-nucleotide motif a holo-3 0 splice
site is composed of three elements: the 3 0AG (the splice site
proper), the branchpoint and the polypyrmidine tract which
are usually spread across the last 40 nucleotides of the intron
but they can take up considerably more space [28,40]. Because
of the lack of space taken up by 5 0 splice sites, proteins bound
in the downstream intron are less likely to disrupt splicing and
the relatively low information content of 5 0 splice sites makes
them sensitive to enhancement. In fact even the archetypal 3 0
splice site inhibitor protein PTB can be an enhancer when
bound downstream of a cassette exon [41]. The Fox proteins
too tend to inhibit exons when bound close to the upstream
3 0 splice contrary to their more usual enhancer role when
bound to the downstream intron [1,22]. A further example of
the asymmetry of action of intronic binding sites comes from
the mutually exclusive exons of FGFR2. In an inducible
Fox-2 expressing cell line a Fox-2 binding site could simulta-
neously enhance the use of the upstream exon IIIb while inhib-
iting the downstream exon IIIc [31].
The same asymmetry is observed with the neural splicing
factor Nova for which over ﬁfty natural targets that have
Nova-aﬀected cassette exons have now been discovered [4].
Mapping the position of Nova binding site-YCAY clusters
in these genes relative to the cassette exons and studying the
direction of the splicing shift in Nova knockout mice showed
that Nova invariably inhibits exon inclusion when bound
around the upstream 3 0 splice site and enhances it when bound
in the vicinity of the 5 0 splice site in the downstream intron. In
fact this tendency to enhance splicing from the downstream
intron and inhibit it from the upstream intron even extends
to the distal positions adjacent to the external constitutive
exons (Fig. 2).
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A caveat to this interpretation of intronic splicing control is
that it only represents primary eﬀects in splicing systems that
are invariably the result of combinations of factors. In other
words, if a protein binds in an intron to inhibit an upstream
exon it may actually be achieving this indirectly by antagoniz-
ing a nearby enhancer [41,42]. Another apparently paradoxical
explanation for downstream intronic splicing inhibitors is that
they may inhibit splicing by actually enhancing splicing of
non-productive or ‘decoy’ splice sites. For example, a perfectly
good 3 0 splice site complete with branchpoint and pyrimidine
tract is found 200 nucleotides downstream of exon 9 of caspase
2 and, without actually being used, this pseudo splice site
causes skipping of the upstream exon [43]. A similar poly-
pyrimidine tract and AG sequence are found 60 nucleotides
downstream of CFTR exon 9. Inhibition of the upstream exon
is caused by the binding of SRp40 and ASF/SF2, 20–60 nucleo-
tides downstream of the decoy 3 0 splice site. These proteins
are normally associated with enhancement of splicing but their
net eﬀect in this context is to stimulate unproductive splicing
complexes that compete with the bona ﬁde exon upstream
and inhibit its inclusion [44].8. Conclusion
The general observation that splicing is often enhanced from
downstream of 5 0 splices sites has belied a simple explanation
as splicing is a cotranscriptional process controlled by a com-
plex machine, the spliceosome, that consists of hundreds of
core and auxiliary proteins as well as catalytic small nuclear
ribonucleoprotein particles (snRNPs) [6]. However, the 5 0
splice site may exert the ultimate control over cassette exon
alternative splicing as it was observed that upstream Nova
silencers inhibited 5 0 splice site occupancy by U1 snRNP
whereas downstream enhancers promoted spliceosome recruit-
ment [4] and crucially, U1 has recently been shown to be a core
component of RNA polymerase itself [45]. Clearly there are
still more questions about introns than answers but they are
undoubtedly of fundamental biological importance and under-
standing them remains one of the great challenges of the post
genomic age.
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